103 related articles for article (PubMed ID: 11207579)
1. The bacterial protein YopJ abrogates multiple signal transduction pathways that converge on the transcription factor CREB.
Meijer LK; Schesser K; Wolf-Watz H; Sassone-Corsi P; Pettersson S
Cell Microbiol; 2000 Jun; 2(3):231-8. PubMed ID: 11207579
[TBL] [Abstract][Full Text] [Related]
2. Interference of eukaryotic signalling pathways by the bacteria Yersinia outer protein YopJ.
Spiik AK; Meijer LK; Ridderstad A; Pettersson S
Immunol Lett; 1999 Jun; 68(2-3):199-203. PubMed ID: 10424421
[TBL] [Abstract][Full Text] [Related]
3.
Sheppe AEF; Santelices J; Czyz DM; Edelmann MJ
Microbiol Spectr; 2021 Sep; 9(1):e0049621. PubMed ID: 34319170
[TBL] [Abstract][Full Text] [Related]
4. YopJ of Yersinia spp. is sufficient to cause downregulation of multiple mitogen-activated protein kinases in eukaryotic cells.
Palmer LE; Pancetti AR; Greenberg S; Bliska JB
Infect Immun; 1999 Feb; 67(2):708-16. PubMed ID: 9916081
[TBL] [Abstract][Full Text] [Related]
5. Uncovering an Important Role for YopJ in the Inhibition of Caspase-1 in Activated Macrophages and Promoting Yersinia pseudotuberculosis Virulence.
Schoberle TJ; Chung LK; McPhee JB; Bogin B; Bliska JB
Infect Immun; 2016 Apr; 84(4):1062-1072. PubMed ID: 26810037
[TBL] [Abstract][Full Text] [Related]
6. YopJ-induced caspase-1 activation in Yersinia-infected macrophages: independent of apoptosis, linked to necrosis, dispensable for innate host defense.
Zheng Y; Lilo S; Mena P; Bliska JB
PLoS One; 2012; 7(4):e36019. PubMed ID: 22563435
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory signalling stimulated by the type III translocation factor YopB is counteracted by multiple effectors in epithelial cells infected with Yersinia pseudotuberculosis.
Viboud GI; So SS; Ryndak MB; Bliska JB
Mol Microbiol; 2003 Mar; 47(5):1305-15. PubMed ID: 12603736
[TBL] [Abstract][Full Text] [Related]
8. YopJ of Yersinia pseudotuberculosis is required for the inhibition of macrophage TNF-alpha production and downregulation of the MAP kinases p38 and JNK.
Palmer LE; Hobbie S; Galán JE; Bliska JB
Mol Microbiol; 1998 Mar; 27(5):953-65. PubMed ID: 9535085
[TBL] [Abstract][Full Text] [Related]
9. Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction.
Meinzer U; Barreau F; Esmiol-Welterlin S; Jung C; Villard C; Léger T; Ben-Mkaddem S; Berrebi D; Dussaillant M; Alnabhani Z; Roy M; Bonacorsi S; Wolf-Watz H; Perroy J; Ollendorff V; Hugot JP
Cell Host Microbe; 2012 Apr; 11(4):337-51. PubMed ID: 22520462
[TBL] [Abstract][Full Text] [Related]
10. Reduced secretion of YopJ by Yersinia limits in vivo cell death but enhances bacterial virulence.
Brodsky IE; Medzhitov R
PLoS Pathog; 2008 May; 4(5):e1000067. PubMed ID: 18483548
[TBL] [Abstract][Full Text] [Related]
11. The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity.
Schesser K; Spiik AK; Dukuzumuremyi JM; Neurath MF; Pettersson S; Wolf-Watz H
Mol Microbiol; 1998 Jun; 28(6):1067-79. PubMed ID: 9680199
[TBL] [Abstract][Full Text] [Related]
12. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction.
Sweet CR; Conlon J; Golenbock DT; Goguen J; Silverman N
Cell Microbiol; 2007 Nov; 9(11):2700-15. PubMed ID: 17608743
[TBL] [Abstract][Full Text] [Related]
13. CREB is activated by UVC through a p38/HOG-1-dependent protein kinase.
Iordanov M; Bender K; Ade T; Schmid W; Sachsenmaier C; Engel K; Gaestel M; Rahmsdorf HJ; Herrlich P
EMBO J; 1997 Mar; 16(5):1009-22. PubMed ID: 9118940
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MAPK and NF-kappa B pathways is necessary for rapid apoptosis in macrophages infected with Yersinia.
Zhang Y; Ting AT; Marcu KB; Bliska JB
J Immunol; 2005 Jun; 174(12):7939-49. PubMed ID: 15944300
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector.
Orth K; Palmer LE; Bao ZQ; Stewart S; Rudolph AE; Bliska JB; Dixon JE
Science; 1999 Sep; 285(5435):1920-3. PubMed ID: 10489373
[TBL] [Abstract][Full Text] [Related]
16. Yersinia YopJ inhibits pro-inflammatory molecule expression in human bronchial epithelial cells.
Zhou L; Tan A; Hershenson MB
Respir Physiol Neurobiol; 2004 Apr; 140(1):89-97. PubMed ID: 15109931
[TBL] [Abstract][Full Text] [Related]
17. The Salmonella YopJ-homologue AvrA does not possess YopJ-like activity.
Schesser K; Dukuzumuremyi JM; Cilio C; Borg S; Wallis TS; Pettersson S; Galyov EE
Microb Pathog; 2000 Feb; 28(2):59-70. PubMed ID: 10644492
[TBL] [Abstract][Full Text] [Related]
18. Comparison of YopE and YopT activities in counteracting host signalling responses to Yersinia pseudotuberculosis infection.
Viboud GI; Mejía E; Bliska JB
Cell Microbiol; 2006 Sep; 8(9):1504-15. PubMed ID: 16922868
[TBL] [Abstract][Full Text] [Related]
19. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease.
Orth K; Xu Z; Mudgett MB; Bao ZQ; Palmer LE; Bliska JB; Mangel WF; Staskawicz B; Dixon JE
Science; 2000 Nov; 290(5496):1594-7. PubMed ID: 11090361
[TBL] [Abstract][Full Text] [Related]
20. YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection.
Zhang Y; Bliska JB
Infect Immun; 2010 May; 78(5):2329-41. PubMed ID: 20231414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
